Molina Healthcare (MOH) Securities Class Action Lawsuit

Shamis & Gentile, P.A. reminds investors of the upcoming lead plaintiff deadline of December 2, 2025 in the class action filed on behalf of investors who purchased or otherwise acquired Molina Healthcare, Inc. ("Molina Healthcare" or the "Company") (MOH) securities between February 5, 2025 and July 23, 2025 (the "Class Period").

Investors who purchased Molina Healthcare securities during the class period may be eligible to serve as lead plaintiff. The deadline to apply to be lead plaintiff is approaching. Contact the firm now for more information on how to participate. The deadline to apply for lead plaintiff is December 2, 2025.

The class action complaint alleges that Molina Healthcare and certain of its executives made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

According to the class action complaint, the truth began to emerge on July 7, 2025, when Molina Healthcare announced preliminary second-quarter results and cut its full-year 2025 adjusted earnings guidance by more than 10%, citing “medical cost pressures in all three lines of business.” Then, on July 23, 2025, after the market closed, Molina reported second-quarter adjusted earnings of $5.48 per share and reduced its full-year adjusted earnings outlook again to no less than $19.00 per share, attributing the cut to a “challenging medical cost trend environment.”

Following these disclosures, Molina’s stock price fell $32.03 per share, or 16.84%, to close at $158.22 on July 24, 2025, causing substantial losses to investors.

If you purchased Molina Healthcare (MOH) securities between February 5, 2025 and July 23, 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile, P.A. today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.